Clinical Trial Update: Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach [NA]

View source ↗

Summary

Ongoing recruitment for a clinical trial evaluating stereotactic adaptive radiation therapy for border-line resectable pancreatic cancer, sponsored by Varian.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Varian, a Siemens Healthineers Company | Conditions: Pancreatic Cancer | NA | Status: RECRUITING